1-Benzyl-1-methyl-4-oxopiperidine-1-ium

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Benzyl-1-methyl-4-oxopiperidine-1-ium
• 英文别名: 1-benzyl-1-methyl-4-oxopiperidin-1-ium；1-benzyl-1-methyl-4-oxo-piperidinium；1-Benzyl-1-methylpiperidin-1-ium-4-one
• 化学式: C₁₃H₁₈NO
• 分子量: 204.292
• InChiKey: OXBUCKZAUJPPAG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  、 1-Benzyl-1-methyl-4-oxopiperidine-1-ium 生成
  参考文献：
  名称：

  摘要：

  DOI：

文献信息

• [EN] UREA COMPOUNDS AND THEIR USE AS FAAH ENZYME INHIBITORS<br/>[FR] COMPOSÉS D'URÉE ET LEUR UTILISATION COMME INHIBITEURS DE L'ENZYME FAAH
  申请人：BIAL PORTELA & Cª S A

  公开号：WO2015016728A1

  公开（公告）日：2015-02-05

  A compound having Formula (I): wherein: R1 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R2 is selected from hydrogen, halogen, hydroxyl and C1-4 alkoxy; R3 is C1-4 alkyl; R4 is aryl which is substituted with a group selected from OSO2NH2, NHCONH2, NHSO2NH2, NHSO2C1-4 alkyl and CONH2; and n is 0 or 1; or a pharmaceutically acceptable salt thereof; provided that the compound is not N-(1-benzylpiperidin-4-yl)-N-methyl-4-(4-(sulfamoylamino)phenyl)-1H-imidazole-1-carboxamide or N-(1-benzylpiperidin-4-yl)-N-methyl-4-(3-(methylsulfonamido)phenyl)-1H-imidazole-1-carboxamide. The compound may be used as an inhibitor of fatty acid amide hydrolase.

  具有以下化学式（I）的化合物：其中：R1从氢、卤素、羟基和C1-4烷氧基中选择；R2从氢、卤素、羟基和C1-4烷氧基中选择；R3是C1-4烷基；R4是芳基，其被从OSO2NH2、NHCONH2、NHSO2NH2、NHSO2C1-4烷基和CONH2中选择的基团取代；n为0或1；或其药学上可接受的盐；前提是该化合物不是N-(1-苄基哌啶-4-基)-N-甲基-4-(4-(磺胺氨基)苯基)-1H-咪唑-1-羧酰胺或N-(1-苄基哌啶-4-基)-N-甲基-4-(3-(甲磺酰氨基)苯基)-1H-咪唑-1-羧酰胺。该化合物可用作脂肪酸酰胺水解酶的抑制剂。
• [EN] TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS DE TÉTRAHYDRO-PYRIDO-PYRIMIDINE
  申请人：NOVARTIS AG

  公开号：WO2012004299A1

  公开（公告）日：2012-01-12

  The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), wherein Y, R1, R2 and m are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of the PI3K enzymes.

  这项发明涉及公式（I）中Y、R1、R2和m所定义的替代四氢吡啶嘧啶衍生物。这些化合物适用于治疗由PI3K酶活性介导的疾病或疾病。
• Use of Inhibitors of the Activity or Function of PI3K
  申请人：NOVARTIS AG

  公开号：US20150342951A1

  公开（公告）日：2015-12-03

  The invention relates to new uses of PI3K inhibitors, wherein said inhibitors have an inhibitory action on the PI3K isoform delta for the treatment of immunopathology in a subject suffering from a disease or disorder selected from malaria, leishmaniasis, trypanosomiasis, toxoplasmosis and/or neurocysticercosis, via functional inhibition of TLR9 of the infected subject.

  该发明涉及PI3K抑制剂的新用途，其中所述抑制剂对PI3K同工酶δ具有抑制作用，用于治疗患有疟疾、利什曼病、锥虫病、弓形虫病和/或神经囊虫病等疾病或紊乱的受试者的免疫病理学，通过对感染受试者的TLR9的功能抑制。
• [EN] SOLID FORMS AND SALTS OF TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES<br/>[FR] FORMES SOLIDES ET SELS DE DÉRIVÉS DE TÉTRAHYDRO-PYRIDO-PYRIMIDINE
  申请人：NOVARTIS AG

  公开号：WO2013001445A1

  公开（公告）日：2013-01-03

  The invention relates to crystalline anhydrous forms, crystalline solvate forms and/or salt forms including crystalline salt forms of (S)-3-[6-(6-methoxy-5-methyl-pyridin-3-yl)-5,6,7,8- tetrahydro-pyrido[4,3-d]pyrimidin-4-yloxy]-pyrrolidin-1-yl}-(tetrahydro-pyran-4-yl)-methanone or salt forms including crystalline salt forms of 1-(S)-3-[6-(6-methoxy-5-trifluoromethyl- pyridin-3-yl)-5,6,7,8-tetrahydro-pyrido[4,3-d]pyrimidin-4-ylamino]-pyrrolidin-1-yl}-propan-1-on; pharmaceutical compositions and combinations including these forms as well as to methods of using these forms, including their pharmaceutical compositions and combinations for the treatment of diseases.

  该发明涉及结晶的无水形式、结晶的溶剂结晶形式和/或盐形式，包括(S)-3-[6-(6-甲氧基-5-甲基吡啶-3-基)-5,6,7,8-四氢-吡啶并[4,3-d]嘧啶-4-氧基]-吡咯烷-1-基}-(四氢吡喃-4-基)-甲酮的结晶盐形式或包括1-(S)-3-[6-(6-甲氧基-5-三氟甲基吡啶-3-基)-5,6,7,8-四氢-吡啶并[4,3-d]嘧啶-4-基氨基]-吡咯烷-1-基}-丙酮的结晶盐形式；包括这些形式的药物组合物和组合物，以及使用这些形式的方法，包括它们的药物组合物和组合物用于治疗疾病。
• SUBSTITUTED BENZIMIDAZOLE-TYPE PIPERIDINE COMPOUNDS AND USES THEREOF
  申请人：Shionogi & Co., Ltd.

  公开号：US20140187535A1

  公开（公告）日：2014-07-03

  The disclosure relates to Substituted Benzimidazole-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable salts or solvates thereof, e.g., a pharmaceutically acceptable salt or solvate, wherein R 1 , R 2 , R 3 , Q a , W, U, A, B, Z, a, and the dashed lines are as defined herein, compositions comprising an effective amount of a Substituted Benzimidazole-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted Benzimidazole-Type Piperidine Compound.

  该披露涉及式(I)的取代苯并咪唑基哌啶化合物及其药学上可接受的盐或溶剂，例如药学上可接受的盐或溶剂，其中R1、R2、R3、Qa、W、U、A、B、Z、a和虚线如本文所定义，包括有效量的取代苯并咪唑基哌啶化合物的组合物，以及治疗或预防疾病的方法，例如疼痛，包括向需要的动物施用有效量的取代苯并咪唑基哌啶化合物。